Similarly, in the CheckMate 498 clinical study, PD-1 blockade in combination with radiotherapy in newly diagnosed GBM patients with unmethylated MGMT promoter failed to meet its primary endpoint of improvement in survival, as the cohort that received the alkylating chemotherapy temozolomide (TMZ) plus radiotherapy showed a longer overall survival (2). This evidence concerns the gene MGMT and glioblastoma.